Tolvaptan (Jinarc) by cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD)

Based on the criteria for mutual replaceability, tolvaptan is not eligible for placing on List 1A of the GVS.

Nor is tolvaptan eligible for placing on List 1B of the GVS. Though it is true that tolvaptan does have an added therapeutic value in slowing the progression of cyst development and renal insufficiency of ADPKD in adults with CKD stage 1 to 3, the methodological quality of the pharmacoeconomic analysis is insufficient to be able to make a reliable statement about its cost-effectiveness. Zorginstituut Nederland therefore advises against including tolvaptan (Jinarc) in the GVS.